TITLE
description
TITLE
description
TITLE
description

Cervical cancer is one of the leading causes of cancer death in women.

Human papillomavirus (HPV) is found in about 99% of cervical cancers. 

Screening can reduce the incidence rates of cervical cancer. 

It can be significantly reduced 

by well-planned & organized management.



Age-standardized incidence rates of cervical cancer


[Data Source: WHO. Preventing chronic disease: a vital investment, Geneva, 2005]

Our solution for Cervical Cancer 

-  Multiplex Real-time PCR

    (14 targets (HPV 16, 18 and Other HR12)simultaneously  

      in a single tube)

- HotStart PCR system : high specificity and sensitivity

- Uracil-DNA glycosylase(UDG)-dUTP system: 

   No carryover contamination

- Reliable result by positive/negative/internal (HBB) control

- Easy to use master mix type

- 99.6% clinical sensitivity, 100% clinical specificity for all 

  detection (HPV16, 18 and Other HR12) with cervical swab

  samples

- Urine sample availabe for detecting 14 target HPVs:

   over 85% agreement with swab samples

- CE-IVD 

□  Specimen

-  Liquid-based cytology specimen

    (ThinPrep / SurePath )

-  Cervical swab

-  Urine sample

 □ Target

- HPV 16

- HPV 18

- HPV Other HR 12 

   (HPV 31, 33, 35, 39, 45, 51, 52, 56, 58, 

     59,66, 68)

 Compatible Instrument

Test Process

Ordering information

If you are interested in this product, please contact us. 

SEJONG BIOMED CO., LTD. 11, Sinchon 2-ro, Paju-si, Gyeonggi-do, 10880, South Korea

T. +82-31-945-1571, E. info@sejongbiomed.com

 COPYRIGHT © 2017 by SEJONG BIOMED CO., LTD.


 Family site : SEJONG MEDICAL CO., LTD. www.sejongmedical.com